Abstracts tagged "Disease Activity and spondylarthritis"

Abstract Number: 2496 • 2019 ACR/ARP Annual Meeting
Serum Metabolomic Analysis of Psoriatic Arthritis Using Solid Phase Microextraction – Liquid Chromatography – High-Resolution Mass Spectrometry Identifies Putative Disease Activity Markers
Vinod Chandran¹, Nikita Looby ², Nathaly Reyes-Garces ², Rohan Machhar ³, Miao Yu ², Anna Roszkowska ², Janusz Pawliszyn ² and Vathany Kulasingam ⁴, ¹University Health Network, University of Toronto, Toronto, Canada, ²University of Waterloo, Waterloo, ON, Canada, ³Krembil Research Institute, University Health Network, Toronto, Canada, ⁴University of Toronto, Toronto, ON, Canada
Background/Purpose: Disease activity in psoriatic arthritis (PsA) is often difficult to assess but drives treatment decisions, joint damage and long-term outcomes. We aimed to identify…
Abstract Number: 2275 • 2015 ACR/ARHP Annual Meeting
The Burden of Axial Spondyloarthritis: A Comparison of the Radiographic and Non-Radiographic Groups
Gokce Kenar¹, Pinar Cetin¹, Gercek Can¹, Sedat Capar², Handan Yarkan¹, Ismail Sari¹, Merih Birlik¹, Fatos Onen¹ and Nurullah Akkoc³, ¹Rheumatology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey, ²Dokuz Eylül University Faculty of Statistics, Izmir, Turkey, ³Department of Rheumatology, Dokuz Eylul University, Faculty of Medicine, Izmir, Turkey
Background/Purpose: Axial spondyloarthritis (axSpA) represents the whole clinical spectrum of ankylosing spondylitis (AS) including those at the non-radiographic (nr) stage of the disease. Although the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].